Display options
Cite
Moschetta M, Mak G, Hauser J, et al. Dabrafenib and trametinib activity in a patient with BRAF V600E mutated and microsatellite instability high (MSI-H) metastatic endometrial cancer. Exp Hematol Oncol. 2017;6:1doi: 10.1186/s40164-016-0061-2.
Moschetta, M., Mak, G., Hauser, J., Davies, C., Uccello, M., & Arkenau, H. T. (2017). Dabrafenib and trametinib activity in a patient with BRAF V600E mutated and microsatellite instability high (MSI-H) metastatic endometrial cancer. Experimental hematology & oncology, 61. https://doi.org/10.1186/s40164-016-0061-2
Moschetta, Michele, et al. "Dabrafenib and trametinib activity in a patient with BRAF V600E mutated and microsatellite instability high (MSI-H) metastatic endometrial cancer." Experimental hematology & oncology vol. 6 (2017): 1. doi: https://doi.org/10.1186/s40164-016-0061-2
Moschetta M, Mak G, Hauser J, Davies C, Uccello M, Arkenau HT. Dabrafenib and trametinib activity in a patient with BRAF V600E mutated and microsatellite instability high (MSI-H) metastatic endometrial cancer. Exp Hematol Oncol. 2017 Jan 10;6:1. doi: 10.1186/s40164-016-0061-2. eCollection 2017. PMID: 28078189; PMCID: PMC5223353.
Copy Download .nbib Format: NLM
Share it on

Exp Hematol Oncol. 2017 Jan 10;6:1. doi: 10.1186/s40164-016-0061-2. eCollection 2017.

Dabrafenib and trametinib activity in a patient with BRAF V600E mutated and microsatellite instability high (MSI-H) metastatic endometrial cancer.

Experimental hematology & oncology

Michele Moschetta, Gabriel Mak, Joana Hauser, Catriona Davies, Mario Uccello, Hendrik-Tobias Arkenau

Affiliations

  1. Drug Development Unit, Sarah Cannon Research Institute, 93 Harley Street, London, W1G 6AD UK ; University College London, London, UK.
  2. Drug Development Unit, Sarah Cannon Research Institute, 93 Harley Street, London, W1G 6AD UK.

PMID: 28078189 PMCID: PMC5223353 DOI: 10.1186/s40164-016-0061-2

Abstract

BACKGROUND: Targeting BRAF V600E mutation has been proven effective in the treatment of several types of cancer. In endometrial adenocarcinoma, the BRAF V600E mutation has been rarely reported. Whether targeting BRAF oncogene may represent a plausible therapeutic strategy for the rare patients with BRAF-mutated endometrial cancer remains to be ascertained in prospective studies.

CASE PRESENTATION: We report herein the case of a heavily pre-treated patient with recurrent microsatellite instability high (MSI-H) BRAF V600E mutated endometrial adenocarcinoma, which was successfully treated with the V600E targeting agent dabrafenib. After developing resistance to this agent, the MEK targeting agent trametinib was added to dabrafenib achieving again a therapeutic response.

CONCLUSIONS: This case shows that dabrafenib both as monotherapy and when combined with trametinib may exert significant therapeutic activity in heavily pretreated BRAF V600E mutated endometrial adenocarcinoma, and highlight potential benefits of personalized treatment in this disease.

Keywords: BRAF V600E mutation; Dabrafenib; Endometrial cancer; Microsatellite instability; Trametinib

References

  1. N Engl J Med. 2015 Jan 1;372(1):30-9 - PubMed
  2. Fam Cancer. 2014 Mar;13(1):1-12 - PubMed
  3. J Natl Cancer Inst. 2013 Aug 7;105(15):1151-6 - PubMed
  4. J Clin Oncol. 2015 Dec 1;33(34):4032-8 - PubMed
  5. Lancet. 2016 Mar 12;387(10023):1094-108 - PubMed
  6. Nature. 2002 Jun 27;417(6892):949-54 - PubMed
  7. N Engl J Med. 2015 Nov 12;373(20):1979 - PubMed
  8. Clin Cancer Res. 2006 Jun 15;12(12):3865; author reply 3865-6 - PubMed
  9. Gynecol Oncol. 2014 Aug;134(2):385-92 - PubMed
  10. N Engl J Med. 2015 Oct 29;373(18):1733-47 - PubMed
  11. Clin Cancer Res. 2007 Mar 1;13(5):1576-83 - PubMed
  12. Lancet Oncol. 2015 Oct;16(13):1324-34 - PubMed
  13. JAMA Oncol. 2015 Dec;1(9):1319-23 - PubMed
  14. Gynecol Oncol. 2014 Aug;134(2):393-402 - PubMed
  15. Medicina (Kaunas). 2014;50(4):216-21 - PubMed
  16. Thyroid. 2015 Jan;25(1):71-7 - PubMed
  17. Lancet. 2012 Jul 28;380(9839):358-65 - PubMed
  18. Gynecol Oncol. 2015 Jul;138(1):30-5 - PubMed
  19. Lancet Oncol. 2016 May;17(5):642-50 - PubMed

Publication Types